Multiple Sclerosis Journal - October 2017 - 1486

Multiple Sclerosis Journal 23(11)
naive RRMS to accurately demonstrate treatment
effects on CD56 cells. Observation over a prolonged
period might confirm whether CD56 cells are associated with MRI activity and may determine their usefulness in predicting disease activity, treatment
response and clinical outcome.
Acknowledgements
The authors thank Prof. Glenn Reeves, immunological advisor, who was essential in reviewing and advising from an immunological perspective in regard to
NK cells and NK subsets as well as interpreting
immune pathological studies.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or
publication of this article.
Funding
The author(s) received no financial support for the
research, authorship and/or publication of this article.

References
1. Bielekova B. Daclizumab therapy for multiple
sclerosis. Neurotherapeutics 2013; 10(1): 55-67.
2. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al.
Regulatory CD56(bright) natural killer cells mediate
immunomodulatory effects of IL-2Ralpha-targeted
therapy (daclizumab) in multiple sclerosis. Proc Natl
Acad Sci U S A 2006; 103(15): 5941-5946.
3. Segal BM. The role of natural killer cells in curbing
neuroinflammation. J Neuroimmunol 2007; 191(1-2):
2-7.
4. Takahashi K, Aranami T, Endoh M, et al. The
regulatory role of natural killer cells in multiple
sclerosis. Brain 2004; 127(Pt 9): 1917-1927.
5. Cooper MA, Fehniger TA and Caligiuri MA. The
biology of human natural killer-cell subsets. Trends
Immunol 2001; 22(11): 633-640.
6. Fu B, Li X, Sun R, et al. Natural killer cells promote
immune tolerance by regulating inflammatory TH17
cells at the human maternal-fetal interface. Proc Natl
Acad Sci U S A 2013; 110(3): E231-E240.

1486

9. Chanvillard C, Jacolik RF, Infante-Duarte C, et al.
The role of natural killer cells in multiple sclerosis
and their therapeutic implications. Front Immunol
2013; 4: 63.
10. Airas L, Saraste M, Rinta S, et al. Immunoregulatory
factors in multiple sclerosis patients during and after
pregnancy: Relevance of natural killer cells. Clin Exp
Immunol 2008; 151(2): 235-243.
11. Saraste M, Vaisanen S, Alanen A, et al.; Finnish
Multiple Sclerosis And Pregnancy Study Group.
Clinical and immunologic evaluation of women with
multiple sclerosis during and after pregnancy. Gend
Med 2007; 4(1): 45-55.
12. Milo R. The efficacy and safety of daclizumab and its
potential role in the treatment of multiple sclerosis.
Ther Adv Neurol Disord 2014; 7(1): 7-21.
13. Nielsen N, Odum N, Urso B, et al. Cytotoxicity of
CD56(bright) NK cells towards autologous activated
CD4+ T cells is mediated through NKG2D, LFA-1
and TRAIL and dampened via CD94/NKG2A. PLoS
ONE 2012; 7(2): e31959.
14. Martin R. Anti-CD25 (daclizumab) monoclonal
antibody therapy in relapsing-remitting multiple
sclerosis. Clin Immunol 2012; 142(1): 9-14.
15. Wynn D, Kaufman M, Montalban X, et al.
Daclizumab in active relapsing multiple sclerosis
(CHOICE study): A phase 2, randomised, doubleblind, placebo-controlled, add-on trial with interferon
beta. Lancet Neurol 2010; 9(4): 381-390.
16. Martínez-Rodríguez JE, López-Botet M, Munteis
E, et al. Natural killer cell phenotype and clinical
response to interferon-beta therapy in multiple
sclerosis. Clin Immunol 2011; 141(3): 348-356.
17. Rotstein DL, Healy BC, Malik MT, et al. Evaluation
of no evidence of disease activity in a 7-year
longitudinal multiple sclerosis cohort. JAMA Neurol
2015; 72(2): 152-158.
18. Roxburgh RH, Seaman SR, Masterman T, et al.
Multiple Sclerosis Severity Score: Using disability
and disease duration to rate disease severity.
Neurology 2005; 64(7): 1144-1151.
19. Skarica M, Eckstein C, Whartenby KA, et al. Novel
mechanisms of immune modulation of natalizumab
in multiple sclerosis patients. J Neuroimmunol 2011;
235(1-2): 70-76.

7. Poli A, Michel T, Thérésine M, et al. CD56bright
natural killer (NK) cells: An important NK cell
subset. Immunology 2009; 126(4): 458-465.

20. Putzki N, Baranwal MK, Tettenborn B, et al. Effects
of natalizumab on circulating B cells, T regulatory
cells and natural killer cells. Eur Neurol 2010; 63(5):
311-317.

8. Béziat V, Duffy D, Quoc SN, et al.
CD56brightCD16+ NK cells: A functional
intermediate stage of NK cell differentiation. J
Immunol 2011; 186(12): 6753-6761.

21. Saraste M, Irjala H and Airas L. Expansion of
CD56bright natural killer cells in the peripheral blood
of multiple sclerosis patients treated with interferonbeta. Neurol Sci 2007; 28: 121-126.

journals.sagepub.com/home/msj
https://journals.sagepub.com/home/msj
Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017
